Treatment of chronic hepatitis C infection in patients with renal failure

Paul Martin, Fabrizio Fabrizi

Research output: Contribution to journalArticle

Abstract

Patients with end-stage renal disease continue to have a high prevalence of hepatitis C virus infection despite screening of blood products and efforts to prevent the transmission of viral hepatitis within dialysis units. Although biochemical dysfunction often is absent in infected patients, an increased rate of mortality from liver disease has been observed in patients on long-term dialysis. In addition, hepatitis C-infected renal transplant recipients have diminished patient and graft survival rates compared with uninfected controls. Antiviral therapy with interferon in renal transplantation candidates has resulted in sustained viral responses that have been durable even after subsequent renal transplantation. Graft dysfunction remains a major concern, limiting the use of interferon after renal transplant. Ribavirin, which accumulates and cannot be removed by dialysis, and may induce hemolysis, generally has been avoided in patients with end-stage renal disease. In pilot studies, cautious use of reduced doses of ribavirin has been possible in this population with close monitoring of hematocrit levels and additional measures to enhance compensatory erythropoiesis.

Original languageEnglish
JournalClinical Gastroenterology and Hepatology
Volume3
Issue numberSUPPL. 2
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Chronic Hepatitis C
Renal Insufficiency
Dialysis
Infection
Ribavirin
Kidney Transplantation
Interferons
Chronic Kidney Failure
Transplants
Kidney
Therapeutics
Erythropoiesis
Graft Survival
Virus Diseases
Hepatitis C
Hemolysis
Hematocrit
Hepacivirus
Hepatitis
Antiviral Agents

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Treatment of chronic hepatitis C infection in patients with renal failure. / Martin, Paul; Fabrizi, Fabrizio.

In: Clinical Gastroenterology and Hepatology, Vol. 3, No. SUPPL. 2, 10.2005.

Research output: Contribution to journalArticle

@article{9e7a62d3bf5e4eb0b44ca6e397831476,
title = "Treatment of chronic hepatitis C infection in patients with renal failure",
abstract = "Patients with end-stage renal disease continue to have a high prevalence of hepatitis C virus infection despite screening of blood products and efforts to prevent the transmission of viral hepatitis within dialysis units. Although biochemical dysfunction often is absent in infected patients, an increased rate of mortality from liver disease has been observed in patients on long-term dialysis. In addition, hepatitis C-infected renal transplant recipients have diminished patient and graft survival rates compared with uninfected controls. Antiviral therapy with interferon in renal transplantation candidates has resulted in sustained viral responses that have been durable even after subsequent renal transplantation. Graft dysfunction remains a major concern, limiting the use of interferon after renal transplant. Ribavirin, which accumulates and cannot be removed by dialysis, and may induce hemolysis, generally has been avoided in patients with end-stage renal disease. In pilot studies, cautious use of reduced doses of ribavirin has been possible in this population with close monitoring of hematocrit levels and additional measures to enhance compensatory erythropoiesis.",
author = "Paul Martin and Fabrizio Fabrizi",
year = "2005",
month = "10",
doi = "10.1016/S1542-3565(05)00710-X",
language = "English",
volume = "3",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Treatment of chronic hepatitis C infection in patients with renal failure

AU - Martin, Paul

AU - Fabrizi, Fabrizio

PY - 2005/10

Y1 - 2005/10

N2 - Patients with end-stage renal disease continue to have a high prevalence of hepatitis C virus infection despite screening of blood products and efforts to prevent the transmission of viral hepatitis within dialysis units. Although biochemical dysfunction often is absent in infected patients, an increased rate of mortality from liver disease has been observed in patients on long-term dialysis. In addition, hepatitis C-infected renal transplant recipients have diminished patient and graft survival rates compared with uninfected controls. Antiviral therapy with interferon in renal transplantation candidates has resulted in sustained viral responses that have been durable even after subsequent renal transplantation. Graft dysfunction remains a major concern, limiting the use of interferon after renal transplant. Ribavirin, which accumulates and cannot be removed by dialysis, and may induce hemolysis, generally has been avoided in patients with end-stage renal disease. In pilot studies, cautious use of reduced doses of ribavirin has been possible in this population with close monitoring of hematocrit levels and additional measures to enhance compensatory erythropoiesis.

AB - Patients with end-stage renal disease continue to have a high prevalence of hepatitis C virus infection despite screening of blood products and efforts to prevent the transmission of viral hepatitis within dialysis units. Although biochemical dysfunction often is absent in infected patients, an increased rate of mortality from liver disease has been observed in patients on long-term dialysis. In addition, hepatitis C-infected renal transplant recipients have diminished patient and graft survival rates compared with uninfected controls. Antiviral therapy with interferon in renal transplantation candidates has resulted in sustained viral responses that have been durable even after subsequent renal transplantation. Graft dysfunction remains a major concern, limiting the use of interferon after renal transplant. Ribavirin, which accumulates and cannot be removed by dialysis, and may induce hemolysis, generally has been avoided in patients with end-stage renal disease. In pilot studies, cautious use of reduced doses of ribavirin has been possible in this population with close monitoring of hematocrit levels and additional measures to enhance compensatory erythropoiesis.

UR - http://www.scopus.com/inward/record.url?scp=26444549397&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26444549397&partnerID=8YFLogxK

U2 - 10.1016/S1542-3565(05)00710-X

DO - 10.1016/S1542-3565(05)00710-X

M3 - Article

C2 - 16234057

AN - SCOPUS:26444549397

VL - 3

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - SUPPL. 2

ER -